The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Huang, Jingcao ^a,b   Wang, Shuiliang ^a,d   Lyu, Hui ^a   Cai, Bo ^a   Yang, XiaoHe ^c   Wang, Jianxiang ^b   Liu, Bolin ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^c NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^d XIAMEN UNIVERSITY   (China)

Author keywords

Breast cancer; erbB2; erbB3; MM 121; SAR256212; Trastuzumab resistance

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; KI 67 ANTIGEN; MM 121 SAR256212; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CULTURE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

MUS; MUS MUSCULUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887389563     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-134     Document Type: Article

References (52)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
2. Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989, 49:2087-2090.
3. Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ, Wood WC. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 1989, 49:7147-7152.
4. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51. 10.1056/NEJMra043186, 17611206.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792. 10.1056/NEJM200103153441101, 11248153.
6. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726. 10.1200/JCO.20.3.719, 11821453.
7. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007, 26:3637-3643. 10.1038/sj.onc.1210379, 17530017.
8. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006, 3:269-280. 10.1038/ncponc0509, 16683005.
9. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007, 18:977-984. 10.1093/annonc/mdl475, 17229773.
10. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000, 19:6115-6121. 10.1038/sj.onc.1203972, 11156524.
11. Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:215-223. 10.1007/s10911-008-9083-7, 18454306.
12. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003, 106:758-765. 10.1002/ijc.11273, 12866037.
13. de Fazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer 2000, 87:487-498. 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J, 10918187.
14. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008, 68:5878-5887. 10.1158/0008-5472.CAN-08-0380, 18632642.
15. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003, 100:8933-8938. 10.1073/pnas.1537685100, 166416, 12853564.
16. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003, 284:54-65. 10.1016/S0014-4827(02)00101-5, 12648465.
17. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA 2010, 107:7692-7697. 10.1073/pnas.1002753107, 2867849, 20351256.
18. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010, 70:2485-2494. 10.1158/0008-5472.CAN-09-3145, 2840205, 20215504.
19. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2009, 2:ra31. 10.1126/scisignal.2000352, 19567914.
20. Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 2013, 73:824-833. 10.1158/0008-5472.CAN-12-1611, 23172311.
21. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012, 11:582-593. 10.1158/1535-7163.MCT-11-0820, 22248472.
22. Foreman PK, Gore M, Kobel PA, Xu L, Yee H, Hannum C, Ho H, Wang SM, Tran HV, Horowitz M, et al. ErbB3 inhibitory surrobodies inhibit tumor cell proliferation in vitro and in vivo. Mol Cancer Ther 2012, 11:1411-1420. 10.1158/1535-7163.MCT-12-0068, 22553357.
23. Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 2010, 21:944-950. 10.1016/j.semcdb.2010.08.007, 2991618, 20816829.
24. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007, 120:1874-1882. 10.1002/ijc.22423, 17266042.
25. Wang S, Huang X, Lee CK, Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 2010, 29:4225-4236. 10.1038/onc.2010.180, 20498641.
26. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 2010, 70:1204-1214. 10.1158/0008-5472.CAN-09-3321, 20103628.
27. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402. 10.1016/j.ccr.2007.08.030, 17936563.
28. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005, 65:11118-11128. 10.1158/0008-5472.CAN-04-3841, 16322262.
29. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004, 64:3981-3986. 10.1158/0008-5472.CAN-03-3900, 15173011.
30. Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle 2011, 10:2959-2966. 10.4161/cc.10.17.16359, 21862872.
31. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006, 232:123-138. 10.1016/j.canlet.2005.01.041, 16458110.
32. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847. 10.1200/JCO.2009.22.1507, 19884552.
33. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004, 96:739-749. 10.1093/jnci/djh131, 15150302.
34. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. Emerging roles of pseudokinases. Trends Cell Biol 2006, 16:443-452. 10.1016/j.tcb.2006.07.003, 16879967.
35. Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005, 1:2005 0008. 1681463, 16729043.
36. Jathal MK, Chen L, Mudryj M, Ghosh PM. Targeting ErbB3: the new RTK(id) on the Prostate Cancer Block. Immunol Endocr Metab Agents Med Chem 2011, 11:131-149. 10.2174/187152211795495643, 3095967, 21603064.
37. Mills GB, Yarden Y. The rebirth of a phoenix: ovarian cancers are addicted to ErbB-3. Cancer Cell 2010, 17:217-218. 10.1016/j.ccr.2010.02.023, 20227035.
38. Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010, 17:298-310. 10.1016/j.ccr.2009.12.047, 2897158, 20227043.
39. Bellati F, Napoletano C, Ruscito I, Liberati M, Panici PB, Nuti M. Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy. J Clin Oncol 2010, 28:e369-e370. author reply e371, 10.1200/JCO.2010.28.6922, 20479394.
40. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012, 122:1066-1075. 10.1172/JCI61226, 3287235, 22326955.
41. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007, 7:1401-1413. 10.1517/14712598.7.9.1401, 17727329.
42. Jin Q, Esteva FJ. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:485-498. 10.1007/s10911-008-9107-3, 19034632.
43. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743. 10.1056/NEJMoa064320, 17192538.
44. Cameron DA, Stein S. Drug Insight: intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 2008, 5:512-520.
45. McArthur H. An overview of HER-targeted therapy with lapatinib in breast cancer. Adv Ther 2009, 26:263-271. 10.1007/s12325-009-0012-y, 19365626.
46. Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008, 30:1426-1447. 10.1016/j.clinthera.2008.08.008, 18803986.
47. Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R, Justice R, Pazdur R. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008, 13:1114-1119. 10.1634/theoncologist.2008-0816, 18849320.
48. Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J, Pry K, Westlund R, Stein SH, Spector NL. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing Breast Cancers. Cancer Res 2007, 67:1170-1175. 10.1158/0008-5472.CAN-06-2101, 17283152.
49. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008, 68:9221-9230. 10.1158/0008-5472.CAN-08-1740, 2587064, 19010894.
50. Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003, 9:511S-515S.
51. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22:3205-3212. 10.1038/sj.onc.1206394, 12761490.
52. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009, 8:2031-2040. 10.4161/cc.8.13.8814, 19440038.